{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:40:16Z","timestamp":1781800816768,"version":"3.54.5"},"reference-count":73,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/14740338.2024.2368822","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T08:17:42Z","timestamp":1718353062000},"page":"969-979","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9432-224X","authenticated-orcid":false,"given":"Alessandro","family":"Lagan\u00e0","sequence":"first","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Bisegna","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Carmosino","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2295-7321","authenticated-orcid":false,"given":"Claudia","family":"Ielo","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7726-2936","authenticated-orcid":false,"given":"Alessandro","family":"Costa","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Torrieri","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Totaro","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"issue":"5","key":"e_1_3_4_4_1","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen MH","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935\u2013942.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1630-5"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2334-x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242891"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1675879"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18883"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.004"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13430"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03549-3"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2604-x"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01205-5"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7054"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7005"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01260-y"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02736-5"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194894"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145611"},{"issue":"1","key":"e_1_3_4_32_1","first-page":"2875","article-title":"Results from ENESTgoal: a phase 2 study of treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who switched from imatinib to nilotinib","volume":"130","author":"Ritchie EK","year":"2017","unstructured":"Ritchie EK, Catchatourian R, Klisovic RB, et al. Results from ENESTgoal: a phase 2 study of treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who switched from imatinib to nilotinib. Blood. 2017;130(Supplement 1):2875.","journal-title":"Blood"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148369"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5774"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26556"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057521"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35721"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194522"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30094-8"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180131"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146221"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.004"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30885"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19058"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18796"},{"key":"e_1_3_4_48_1","unstructured":"Japan Registry of Clinical Trials. Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase (JALSG CML RE-STOP219). [cited 2020 Feb 17]. Available from: https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCTs041190117"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1590964"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205054"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1154377"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1101743"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2896"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1094"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3373"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131500"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31977"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165001"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.360"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00194"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0684-5"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14085"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5158"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14973"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020002538"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.6910"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189925"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24495"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16245"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280740"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000157"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967536.34543.a6"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160138"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151966"},{"issue":"5","key":"e_1_3_4_75_1","first-page":"591","article-title":"Monitoring treatment-free remission by droplet digital PCR in CML patients with deep molecular response to tyrosine kinase inhibitor: an analysis based on real-world data","volume":"50","author":"Zhu G","year":"2020","unstructured":"Zhu G, Yang Y, Wang H, et al. Monitoring treatment-free remission by droplet digital PCR in CML patients with deep molecular response to tyrosine kinase inhibitor: an analysis based on real-world data. Ann Clin Lab Sci. 2020;50(5):591\u2013599.","journal-title":"Ann Clin Lab Sci"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2368822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:30:09Z","timestamp":1727202609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2368822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/14740338.2024.2368822"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2368822","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}